The 2010 McDonald criteria for the diagnosis of multiple sclerosis are widely used in research
and clinical practice. Scientific advances in the past 7 years suggest that they might no …

… Furthermore, therapy is mainly based on standard protocols for aquaporin-4 antibody-associated
NMOSD and multiple sclerosis, and more evidence is needed regarding how and …

Traditionally, multiple sclerosis has been categorised by distinct clinical descriptors—relapsing-remitting,
secondary progressive, and primary progressive—for patient care, research, …

… Multiple strands of evidence suggest that much of the remaining heritability is also due to …
Here, we show in 68,379 cases and controls that up to 5% of this heritability is explained by …

We assembled and analyzed genetic data of 47,351 multiple sclerosis (MS) subjects and
68,284 control subjects and establish a reference map of the genetic architecture of MS that …

… Azathioprine is administered mainly during the relapsing–remitting phase of multiple … it is
usually stopped when the disease becomes progressive. Cyclophosphamide therapy is used …

Background: There is no consensus method for determining progression of disability in patients
with multiple sclerosis (MS) when each patient has had only a single assessment in the …

… The originality of our study is that it is the first to assess the possible influence of the same
clinical variables on the progression of irreversible disability from the time of assignment of a …

… Data are entered retrospectively when the patient is first seen at the clinic. A specific
effort is always made to obtain data from the original medical files, especially for the first …

… In our experience thus far, NMO-IgG is not simply a marker for underlying systemic
autoimmune disease, because no patient with Sjögren's syndrome without neurological …